nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—Vismodegib—Sulfasalazine—rheumatoid arthritis	0.43	1	CrCrCtD
Sorafenib—ABCG2—Leflunomide—rheumatoid arthritis	0.0218	0.073	CbGbCtD
Sorafenib—ABCC2—Sulfasalazine—rheumatoid arthritis	0.0149	0.0499	CbGbCtD
Sorafenib—ABCG2—Sulfasalazine—rheumatoid arthritis	0.0135	0.0451	CbGbCtD
Sorafenib—ABCC2—Cyclosporine—rheumatoid arthritis	0.0113	0.0378	CbGbCtD
Sorafenib—ABCG2—Hydrocortisone—rheumatoid arthritis	0.0108	0.0362	CbGbCtD
Sorafenib—ABCG2—Cyclosporine—rheumatoid arthritis	0.0102	0.0342	CbGbCtD
Sorafenib—ABCC4—Methotrexate—rheumatoid arthritis	0.01	0.0336	CbGbCtD
Sorafenib—CYP1A2—Leflunomide—rheumatoid arthritis	0.00898	0.0301	CbGbCtD
Sorafenib—CYP2C9—Leflunomide—rheumatoid arthritis	0.00809	0.0271	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Hydrocortisone—rheumatoid arthritis	0.00798	0.0267	CbGbCtD
Sorafenib—CYP3A7—Hydrocortisone—rheumatoid arthritis	0.00798	0.0267	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Cyclosporine—rheumatoid arthritis	0.00753	0.0252	CbGbCtD
Sorafenib—CYP3A7—Cyclosporine—rheumatoid arthritis	0.00753	0.0252	CbGbCtD
Sorafenib—CYP3A5—Sulfasalazine—rheumatoid arthritis	0.00746	0.025	CbGbCtD
Sorafenib—ABCC2—Dexamethasone—rheumatoid arthritis	0.00743	0.0249	CbGbCtD
Sorafenib—ABCG2—Dexamethasone—rheumatoid arthritis	0.00672	0.0225	CbGbCtD
Sorafenib—ABCB1—Methylprednisolone—rheumatoid arthritis	0.0064	0.0215	CbGbCtD
Sorafenib—CYP3A5—Hydrocortisone—rheumatoid arthritis	0.00598	0.0201	CbGbCtD
Sorafenib—ABCC2—Methotrexate—rheumatoid arthritis	0.00597	0.02	CbGbCtD
Sorafenib—CYP2C8—Hydrocortisone—rheumatoid arthritis	0.00575	0.0193	CbGbCtD
Sorafenib—CYP3A5—Cyclosporine—rheumatoid arthritis	0.00565	0.0189	CbGbCtD
Sorafenib—CYP2C8—Cyclosporine—rheumatoid arthritis	0.00543	0.0182	CbGbCtD
Sorafenib—ABCG2—Methotrexate—rheumatoid arthritis	0.0054	0.0181	CbGbCtD
Sorafenib—CYP3A4—Ergocalciferol—rheumatoid arthritis	0.0052	0.0174	CbGbCtD
Sorafenib—CYP3A7—Dexamethasone—rheumatoid arthritis	0.00496	0.0166	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Dexamethasone—rheumatoid arthritis	0.00496	0.0166	CbGbCtD
Sorafenib—CYP2C19—Prednisone—rheumatoid arthritis	0.00481	0.0161	CbGbCtD
Sorafenib—CYP2B6—Dexamethasone—rheumatoid arthritis	0.00472	0.0158	CbGbCtD
Sorafenib—CYP2C19—Cyclosporine—rheumatoid arthritis	0.00456	0.0153	CbGbCtD
Sorafenib—ABCB1—Betamethasone—rheumatoid arthritis	0.00416	0.014	CbGbCtD
Sorafenib—ABCB1—Prednisolone—rheumatoid arthritis	0.00411	0.0138	CbGbCtD
Sorafenib—ABCB1—Hydrocortisone—rheumatoid arthritis	0.00389	0.0131	CbGbCtD
Sorafenib—ABCB1—Prednisone—rheumatoid arthritis	0.00388	0.013	CbGbCtD
Sorafenib—CYP3A4—Methylprednisolone—rheumatoid arthritis	0.00384	0.0129	CbGbCtD
Sorafenib—CYP2C9—Cyclosporine—rheumatoid arthritis	0.00379	0.0127	CbGbCtD
Sorafenib—CYP3A5—Dexamethasone—rheumatoid arthritis	0.00372	0.0125	CbGbCtD
Sorafenib—ABCB1—Cyclosporine—rheumatoid arthritis	0.00368	0.0123	CbGbCtD
Sorafenib—CYP2C8—Dexamethasone—rheumatoid arthritis	0.00358	0.012	CbGbCtD
Sorafenib—CYP2D6—Cyclosporine—rheumatoid arthritis	0.00347	0.0116	CbGbCtD
Sorafenib—CYP2C19—Dexamethasone—rheumatoid arthritis	0.003	0.0101	CbGbCtD
Sorafenib—CYP3A4—Triamcinolone—rheumatoid arthritis	0.00291	0.00974	CbGbCtD
Sorafenib—CYP2C9—Dexamethasone—rheumatoid arthritis	0.0025	0.00836	CbGbCtD
Sorafenib—CYP3A4—Betamethasone—rheumatoid arthritis	0.00249	0.00836	CbGbCtD
Sorafenib—CYP3A4—Prednisolone—rheumatoid arthritis	0.00246	0.00825	CbGbCtD
Sorafenib—ABCB1—Dexamethasone—rheumatoid arthritis	0.00242	0.00812	CbGbCtD
Sorafenib—CYP3A4—Hydrocortisone—rheumatoid arthritis	0.00233	0.00782	CbGbCtD
Sorafenib—CYP3A4—Prednisone—rheumatoid arthritis	0.00232	0.00779	CbGbCtD
Sorafenib—CYP2D6—Dexamethasone—rheumatoid arthritis	0.00228	0.00765	CbGbCtD
Sorafenib—CYP3A4—Cyclosporine—rheumatoid arthritis	0.0022	0.00738	CbGbCtD
Sorafenib—ABCB1—Methotrexate—rheumatoid arthritis	0.00195	0.00652	CbGbCtD
Sorafenib—CYP3A4—Dexamethasone—rheumatoid arthritis	0.00145	0.00486	CbGbCtD
Sorafenib—MUSK—tendon—rheumatoid arthritis	0.00143	0.0358	CbGeAlD
Sorafenib—CDK7—connective tissue—rheumatoid arthritis	0.000893	0.0223	CbGeAlD
Sorafenib—HIPK3—connective tissue—rheumatoid arthritis	0.000756	0.0189	CbGeAlD
Sorafenib—KIT—exocrine gland—rheumatoid arthritis	0.000742	0.0185	CbGeAlD
Sorafenib—EPHX2—parotid gland—rheumatoid arthritis	0.000735	0.0184	CbGeAlD
Sorafenib—CDK7—lymphoid tissue—rheumatoid arthritis	0.000653	0.0163	CbGeAlD
Sorafenib—FLT3—connective tissue—rheumatoid arthritis	0.000643	0.0161	CbGeAlD
Sorafenib—MAP3K7—parotid gland—rheumatoid arthritis	0.000619	0.0155	CbGeAlD
Sorafenib—TAOK2—tendon—rheumatoid arthritis	0.000609	0.0152	CbGeAlD
Sorafenib—AURKC—tendon—rheumatoid arthritis	0.000605	0.0151	CbGeAlD
Sorafenib—MKNK2—parotid gland—rheumatoid arthritis	0.0006	0.015	CbGeAlD
Sorafenib—MAP3K7—saliva-secreting gland—rheumatoid arthritis	0.000593	0.0148	CbGeAlD
Sorafenib—MKNK2—saliva-secreting gland—rheumatoid arthritis	0.000575	0.0144	CbGeAlD
Sorafenib—ZAK—lymphoid tissue—rheumatoid arthritis	0.000565	0.0141	CbGeAlD
Sorafenib—ZAK—digestive system—rheumatoid arthritis	0.000558	0.0139	CbGeAlD
Sorafenib—HIPK3—digestive system—rheumatoid arthritis	0.000546	0.0136	CbGeAlD
Sorafenib—RALBP1—parotid gland—rheumatoid arthritis	0.000542	0.0136	CbGeAlD
Sorafenib—ZAK—tendon—rheumatoid arthritis	0.000531	0.0133	CbGeAlD
Sorafenib—MKNK2—connective tissue—rheumatoid arthritis	0.000528	0.0132	CbGeAlD
Sorafenib—HIPK3—tendon—rheumatoid arthritis	0.000519	0.013	CbGeAlD
Sorafenib—RALBP1—saliva-secreting gland—rheumatoid arthritis	0.000519	0.013	CbGeAlD
Sorafenib—FLT1—parotid gland—rheumatoid arthritis	0.000516	0.0129	CbGeAlD
Sorafenib—RET—connective tissue—rheumatoid arthritis	0.000515	0.0129	CbGeAlD
Sorafenib—RAF1—parotid gland—rheumatoid arthritis	0.000513	0.0128	CbGeAlD
Sorafenib—EPHB6—parotid gland—rheumatoid arthritis	0.00051	0.0127	CbGeAlD
Sorafenib—FLT1—saliva-secreting gland—rheumatoid arthritis	0.000494	0.0123	CbGeAlD
Sorafenib—RAF1—saliva-secreting gland—rheumatoid arthritis	0.000491	0.0123	CbGeAlD
Sorafenib—EPHB6—saliva-secreting gland—rheumatoid arthritis	0.000488	0.0122	CbGeAlD
Sorafenib—FLT3—lymphoid tissue—rheumatoid arthritis	0.00047	0.0117	CbGeAlD
Sorafenib—BRAF—tendon—rheumatoid arthritis	0.000465	0.0116	CbGeAlD
Sorafenib—FLT1—connective tissue—rheumatoid arthritis	0.000454	0.0113	CbGeAlD
Sorafenib—RAF1—connective tissue—rheumatoid arthritis	0.000451	0.0113	CbGeAlD
Sorafenib—EPHX2—tendon—rheumatoid arthritis	0.000445	0.0111	CbGeAlD
Sorafenib—MAP2K5—parotid gland—rheumatoid arthritis	0.000436	0.0109	CbGeAlD
Sorafenib—KDR—parotid gland—rheumatoid arthritis	0.000436	0.0109	CbGeAlD
Sorafenib—UGT1A9—digestive system—rheumatoid arthritis	0.000427	0.0107	CbGeAlD
Sorafenib—FLT4—lymphoid tissue—rheumatoid arthritis	0.000427	0.0107	CbGeAlD
Sorafenib—PDGFRA—connective tissue—rheumatoid arthritis	0.000425	0.0106	CbGeAlD
Sorafenib—MAP2K5—saliva-secreting gland—rheumatoid arthritis	0.000417	0.0104	CbGeAlD
Sorafenib—KDR—saliva-secreting gland—rheumatoid arthritis	0.000417	0.0104	CbGeAlD
Sorafenib—FGFR1—tendon—rheumatoid arthritis	0.000396	0.00989	CbGeAlD
Sorafenib—MKNK2—lymphoid tissue—rheumatoid arthritis	0.000386	0.00966	CbGeAlD
Sorafenib—KIT—parotid gland—rheumatoid arthritis	0.000386	0.00965	CbGeAlD
Sorafenib—KDR—connective tissue—rheumatoid arthritis	0.000384	0.00959	CbGeAlD
Sorafenib—MKNK2—digestive system—rheumatoid arthritis	0.000382	0.00954	CbGeAlD
Sorafenib—MKNK1—lymphoid tissue—rheumatoid arthritis	0.000381	0.00953	CbGeAlD
Sorafenib—PDGFRB—parotid gland—rheumatoid arthritis	0.000377	0.00943	CbGeAlD
Sorafenib—MKNK1—digestive system—rheumatoid arthritis	0.000377	0.00942	CbGeAlD
Sorafenib—RET—lymphoid tissue—rheumatoid arthritis	0.000377	0.00942	CbGeAlD
Sorafenib—MAP3K7—tendon—rheumatoid arthritis	0.000375	0.00936	CbGeAlD
Sorafenib—CSF1R—connective tissue—rheumatoid arthritis	0.000374	0.00936	CbGeAlD
Sorafenib—RET—digestive system—rheumatoid arthritis	0.000372	0.0093	CbGeAlD
Sorafenib—KIT—saliva-secreting gland—rheumatoid arthritis	0.00037	0.00925	CbGeAlD
Sorafenib—MKNK2—tendon—rheumatoid arthritis	0.000363	0.00908	CbGeAlD
Sorafenib—PDGFRB—saliva-secreting gland—rheumatoid arthritis	0.000361	0.00903	CbGeAlD
Sorafenib—RET—tendon—rheumatoid arthritis	0.000354	0.00885	CbGeAlD
Sorafenib—RALBP1—digestive system—rheumatoid arthritis	0.000345	0.00861	CbGeAlD
Sorafenib—KIT—connective tissue—rheumatoid arthritis	0.00034	0.0085	CbGeAlD
Sorafenib—PDGFRB—connective tissue—rheumatoid arthritis	0.000332	0.0083	CbGeAlD
Sorafenib—FLT1—lymphoid tissue—rheumatoid arthritis	0.000332	0.00829	CbGeAlD
Sorafenib—RAF1—lymphoid tissue—rheumatoid arthritis	0.00033	0.00825	CbGeAlD
Sorafenib—RALBP1—tendon—rheumatoid arthritis	0.000328	0.0082	CbGeAlD
Sorafenib—FLT1—digestive system—rheumatoid arthritis	0.000328	0.00819	CbGeAlD
Sorafenib—RAF1—digestive system—rheumatoid arthritis	0.000326	0.00814	CbGeAlD
Sorafenib—STK10—lymphoid tissue—rheumatoid arthritis	0.000314	0.00785	CbGeAlD
Sorafenib—FLT1—tendon—rheumatoid arthritis	0.000312	0.0078	CbGeAlD
Sorafenib—PDGFRA—lymphoid tissue—rheumatoid arthritis	0.000311	0.00777	CbGeAlD
Sorafenib—STK10—digestive system—rheumatoid arthritis	0.00031	0.00775	CbGeAlD
Sorafenib—RAF1—tendon—rheumatoid arthritis	0.00031	0.00775	CbGeAlD
Sorafenib—EPHB6—tendon—rheumatoid arthritis	0.000308	0.00771	CbGeAlD
Sorafenib—PDGFRA—digestive system—rheumatoid arthritis	0.000307	0.00768	CbGeAlD
Sorafenib—STK10—tendon—rheumatoid arthritis	0.000295	0.00738	CbGeAlD
Sorafenib—UGT1A1—digestive system—rheumatoid arthritis	0.000293	0.00732	CbGeAlD
Sorafenib—PDGFRA—tendon—rheumatoid arthritis	0.000292	0.00731	CbGeAlD
Sorafenib—KDR—lymphoid tissue—rheumatoid arthritis	0.00028	0.00701	CbGeAlD
Sorafenib—KDR—digestive system—rheumatoid arthritis	0.000277	0.00693	CbGeAlD
Sorafenib—CSF1R—lymphoid tissue—rheumatoid arthritis	0.000274	0.00684	CbGeAlD
Sorafenib—CSF1R—digestive system—rheumatoid arthritis	0.00027	0.00676	CbGeAlD
Sorafenib—MAP2K5—tendon—rheumatoid arthritis	0.000264	0.00659	CbGeAlD
Sorafenib—KDR—tendon—rheumatoid arthritis	0.000264	0.00659	CbGeAlD
Sorafenib—CSF1R—tendon—rheumatoid arthritis	0.000257	0.00643	CbGeAlD
Sorafenib—KIT—lymphoid tissue—rheumatoid arthritis	0.000249	0.00621	CbGeAlD
Sorafenib—KIT—digestive system—rheumatoid arthritis	0.000246	0.00614	CbGeAlD
Sorafenib—PDGFRB—lymphoid tissue—rheumatoid arthritis	0.000243	0.00607	CbGeAlD
Sorafenib—PDGFRB—digestive system—rheumatoid arthritis	0.00024	0.00599	CbGeAlD
Sorafenib—PDGFRB—tendon—rheumatoid arthritis	0.000228	0.0057	CbGeAlD
Sorafenib—ABCG2—parotid gland—rheumatoid arthritis	0.000212	0.0053	CbGeAlD
Sorafenib—ABCG2—saliva-secreting gland—rheumatoid arthritis	0.000203	0.00508	CbGeAlD
Sorafenib—ABCC4—digestive system—rheumatoid arthritis	0.000191	0.00477	CbGeAlD
Sorafenib—HTR2B—digestive system—rheumatoid arthritis	0.00019	0.00475	CbGeAlD
Sorafenib—ABCC2—digestive system—rheumatoid arthritis	0.000185	0.00462	CbGeAlD
Sorafenib—ABCC4—tendon—rheumatoid arthritis	0.000182	0.00454	CbGeAlD
Sorafenib—HTR2B—tendon—rheumatoid arthritis	0.000181	0.00452	CbGeAlD
Sorafenib—ABCC2—tendon—rheumatoid arthritis	0.000176	0.0044	CbGeAlD
Sorafenib—CYP2C19—digestive system—rheumatoid arthritis	0.000159	0.00397	CbGeAlD
Sorafenib—CYP1A2—digestive system—rheumatoid arthritis	0.00013	0.00324	CbGeAlD
Sorafenib—CYP2B6—lymphoid tissue—rheumatoid arthritis	0.000126	0.00315	CbGeAlD
Sorafenib—CYP3A5—digestive system—rheumatoid arthritis	0.000125	0.00313	CbGeAlD
Sorafenib—CYP2B6—digestive system—rheumatoid arthritis	0.000124	0.00311	CbGeAlD
Sorafenib—CYP2C9—digestive system—rheumatoid arthritis	0.000123	0.00308	CbGeAlD
Sorafenib—CYP3A4—digestive system—rheumatoid arthritis	9.39e-05	0.00235	CbGeAlD
Sorafenib—CYP2D6—digestive system—rheumatoid arthritis	9.24e-05	0.00231	CbGeAlD
Sorafenib—ABCB1—lymphoid tissue—rheumatoid arthritis	6.73e-05	0.00168	CbGeAlD
Sorafenib—ABCB1—digestive system—rheumatoid arthritis	6.65e-05	0.00166	CbGeAlD
Sorafenib—Gastrointestinal disorder—Cyclosporine—rheumatoid arthritis	6.32e-05	0.000619	CcSEcCtD
Sorafenib—Skin disorder—Hydrocortisone—rheumatoid arthritis	6.32e-05	0.000619	CcSEcCtD
Sorafenib—Fatigue—Cyclosporine—rheumatoid arthritis	6.31e-05	0.000618	CcSEcCtD
Sorafenib—Headache—Azathioprine—rheumatoid arthritis	6.29e-05	0.000617	CcSEcCtD
Sorafenib—Stevens-Johnson syndrome—Methotrexate—rheumatoid arthritis	6.29e-05	0.000616	CcSEcCtD
Sorafenib—Dizziness—Leflunomide—rheumatoid arthritis	6.27e-05	0.000615	CcSEcCtD
Sorafenib—Constipation—Cyclosporine—rheumatoid arthritis	6.26e-05	0.000613	CcSEcCtD
Sorafenib—Pain—Cyclosporine—rheumatoid arthritis	6.26e-05	0.000613	CcSEcCtD
Sorafenib—Dry mouth—Triamcinolone—rheumatoid arthritis	6.25e-05	0.000612	CcSEcCtD
Sorafenib—Renal failure—Methotrexate—rheumatoid arthritis	6.24e-05	0.000611	CcSEcCtD
Sorafenib—Angioedema—Betamethasone—rheumatoid arthritis	6.23e-05	0.00061	CcSEcCtD
Sorafenib—Angioedema—Dexamethasone—rheumatoid arthritis	6.23e-05	0.00061	CcSEcCtD
Sorafenib—Anorexia—Hydrocortisone—rheumatoid arthritis	6.2e-05	0.000608	CcSEcCtD
Sorafenib—Stomatitis—Methotrexate—rheumatoid arthritis	6.19e-05	0.000606	CcSEcCtD
Sorafenib—Angiopathy—Prednisone—rheumatoid arthritis	6.18e-05	0.000606	CcSEcCtD
Sorafenib—Immune system disorder—Prednisone—rheumatoid arthritis	6.16e-05	0.000603	CcSEcCtD
Sorafenib—Anaphylactic shock—Triamcinolone—rheumatoid arthritis	6.13e-05	0.0006	CcSEcCtD
Sorafenib—Anaphylactic shock—Methylprednisolone—rheumatoid arthritis	6.11e-05	0.000599	CcSEcCtD
Sorafenib—Syncope—Dexamethasone—rheumatoid arthritis	6.11e-05	0.000598	CcSEcCtD
Sorafenib—Syncope—Betamethasone—rheumatoid arthritis	6.11e-05	0.000598	CcSEcCtD
Sorafenib—Arrhythmia—Prednisone—rheumatoid arthritis	6.09e-05	0.000596	CcSEcCtD
Sorafenib—Infection—Triamcinolone—rheumatoid arthritis	6.09e-05	0.000596	CcSEcCtD
Sorafenib—Infection—Methylprednisolone—rheumatoid arthritis	6.07e-05	0.000595	CcSEcCtD
Sorafenib—Vomiting—Leflunomide—rheumatoid arthritis	6.03e-05	0.000591	CcSEcCtD
Sorafenib—Shock—Triamcinolone—rheumatoid arthritis	6.03e-05	0.000591	CcSEcCtD
Sorafenib—Alopecia—Prednisone—rheumatoid arthritis	6.02e-05	0.00059	CcSEcCtD
Sorafenib—Shock—Methylprednisolone—rheumatoid arthritis	6.02e-05	0.000589	CcSEcCtD
Sorafenib—Hepatobiliary disease—Methotrexate—rheumatoid arthritis	6e-05	0.000588	CcSEcCtD
Sorafenib—Nervous system disorder—Methylprednisolone—rheumatoid arthritis	6e-05	0.000587	CcSEcCtD
Sorafenib—Gastrointestinal pain—Cyclosporine—rheumatoid arthritis	5.99e-05	0.000587	CcSEcCtD
Sorafenib—Loss of consciousness—Betamethasone—rheumatoid arthritis	5.99e-05	0.000587	CcSEcCtD
Sorafenib—Loss of consciousness—Dexamethasone—rheumatoid arthritis	5.99e-05	0.000587	CcSEcCtD
Sorafenib—Epistaxis—Methotrexate—rheumatoid arthritis	5.99e-05	0.000586	CcSEcCtD
Sorafenib—Rash—Leflunomide—rheumatoid arthritis	5.98e-05	0.000586	CcSEcCtD
Sorafenib—Dermatitis—Leflunomide—rheumatoid arthritis	5.98e-05	0.000585	CcSEcCtD
Sorafenib—Mental disorder—Prednisone—rheumatoid arthritis	5.97e-05	0.000585	CcSEcCtD
Sorafenib—Nausea—Azathioprine—rheumatoid arthritis	5.97e-05	0.000585	CcSEcCtD
Sorafenib—Headache—Leflunomide—rheumatoid arthritis	5.94e-05	0.000582	CcSEcCtD
Sorafenib—Skin disorder—Methylprednisolone—rheumatoid arthritis	5.94e-05	0.000582	CcSEcCtD
Sorafenib—Erythema—Prednisone—rheumatoid arthritis	5.93e-05	0.000581	CcSEcCtD
Sorafenib—Malnutrition—Prednisone—rheumatoid arthritis	5.93e-05	0.000581	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Hydrocortisone—rheumatoid arthritis	5.93e-05	0.000581	CcSEcCtD
Sorafenib—Hypertension—Betamethasone—rheumatoid arthritis	5.88e-05	0.000576	CcSEcCtD
Sorafenib—Hypertension—Dexamethasone—rheumatoid arthritis	5.88e-05	0.000576	CcSEcCtD
Sorafenib—Urticaria—Cyclosporine—rheumatoid arthritis	5.82e-05	0.00057	CcSEcCtD
Sorafenib—Myalgia—Dexamethasone—rheumatoid arthritis	5.8e-05	0.000568	CcSEcCtD
Sorafenib—Myalgia—Betamethasone—rheumatoid arthritis	5.8e-05	0.000568	CcSEcCtD
Sorafenib—Abdominal pain—Cyclosporine—rheumatoid arthritis	5.79e-05	0.000567	CcSEcCtD
Sorafenib—Body temperature increased—Cyclosporine—rheumatoid arthritis	5.79e-05	0.000567	CcSEcCtD
Sorafenib—Dyspepsia—Hydrocortisone—rheumatoid arthritis	5.73e-05	0.000561	CcSEcCtD
Sorafenib—Haemoglobin—Methotrexate—rheumatoid arthritis	5.73e-05	0.000561	CcSEcCtD
Sorafenib—Pain—Prednisolone—rheumatoid arthritis	5.7e-05	0.000558	CcSEcCtD
Sorafenib—Haemorrhage—Methotrexate—rheumatoid arthritis	5.7e-05	0.000558	CcSEcCtD
Sorafenib—Decreased appetite—Hydrocortisone—rheumatoid arthritis	5.66e-05	0.000554	CcSEcCtD
Sorafenib—Nausea—Leflunomide—rheumatoid arthritis	5.64e-05	0.000552	CcSEcCtD
Sorafenib—Urinary tract disorder—Methotrexate—rheumatoid arthritis	5.63e-05	0.000551	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Hydrocortisone—rheumatoid arthritis	5.62e-05	0.00055	CcSEcCtD
Sorafenib—Fatigue—Hydrocortisone—rheumatoid arthritis	5.61e-05	0.00055	CcSEcCtD
Sorafenib—Urethral disorder—Methotrexate—rheumatoid arthritis	5.58e-05	0.000547	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Triamcinolone—rheumatoid arthritis	5.58e-05	0.000547	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Methylprednisolone—rheumatoid arthritis	5.57e-05	0.000546	CcSEcCtD
Sorafenib—Pain—Hydrocortisone—rheumatoid arthritis	5.57e-05	0.000545	CcSEcCtD
Sorafenib—Anaphylactic shock—Dexamethasone—rheumatoid arthritis	5.56e-05	0.000545	CcSEcCtD
Sorafenib—Anaphylactic shock—Betamethasone—rheumatoid arthritis	5.56e-05	0.000545	CcSEcCtD
Sorafenib—Infection—Dexamethasone—rheumatoid arthritis	5.52e-05	0.000541	CcSEcCtD
Sorafenib—Infection—Betamethasone—rheumatoid arthritis	5.52e-05	0.000541	CcSEcCtD
Sorafenib—Anaemia—Prednisone—rheumatoid arthritis	5.48e-05	0.000537	CcSEcCtD
Sorafenib—Shock—Betamethasone—rheumatoid arthritis	5.47e-05	0.000536	CcSEcCtD
Sorafenib—Shock—Dexamethasone—rheumatoid arthritis	5.47e-05	0.000536	CcSEcCtD
Sorafenib—Dyspnoea—Triamcinolone—rheumatoid arthritis	5.46e-05	0.000535	CcSEcCtD
Sorafenib—Nervous system disorder—Dexamethasone—rheumatoid arthritis	5.45e-05	0.000534	CcSEcCtD
Sorafenib—Nervous system disorder—Betamethasone—rheumatoid arthritis	5.45e-05	0.000534	CcSEcCtD
Sorafenib—Thrombocytopenia—Betamethasone—rheumatoid arthritis	5.44e-05	0.000533	CcSEcCtD
Sorafenib—Thrombocytopenia—Dexamethasone—rheumatoid arthritis	5.44e-05	0.000533	CcSEcCtD
Sorafenib—Angioedema—Prednisone—rheumatoid arthritis	5.42e-05	0.000531	CcSEcCtD
Sorafenib—Hypersensitivity—Cyclosporine—rheumatoid arthritis	5.4e-05	0.000528	CcSEcCtD
Sorafenib—Dyspepsia—Triamcinolone—rheumatoid arthritis	5.39e-05	0.000528	CcSEcCtD
Sorafenib—Erythema multiforme—Methotrexate—rheumatoid arthritis	5.39e-05	0.000528	CcSEcCtD
Sorafenib—Dyspepsia—Methylprednisolone—rheumatoid arthritis	5.38e-05	0.000527	CcSEcCtD
Sorafenib—Gastrointestinal pain—Hydrocortisone—rheumatoid arthritis	5.32e-05	0.000521	CcSEcCtD
Sorafenib—Syncope—Prednisone—rheumatoid arthritis	5.32e-05	0.000521	CcSEcCtD
Sorafenib—Tinnitus—Methotrexate—rheumatoid arthritis	5.31e-05	0.00052	CcSEcCtD
Sorafenib—Anorexia—Betamethasone—rheumatoid arthritis	5.3e-05	0.000519	CcSEcCtD
Sorafenib—Anorexia—Dexamethasone—rheumatoid arthritis	5.3e-05	0.000519	CcSEcCtD
Sorafenib—Urticaria—Prednisolone—rheumatoid arthritis	5.29e-05	0.000519	CcSEcCtD
Sorafenib—Cardiac disorder—Methotrexate—rheumatoid arthritis	5.29e-05	0.000518	CcSEcCtD
Sorafenib—Fatigue—Triamcinolone—rheumatoid arthritis	5.28e-05	0.000518	CcSEcCtD
Sorafenib—Fatigue—Methylprednisolone—rheumatoid arthritis	5.27e-05	0.000516	CcSEcCtD
Sorafenib—Asthenia—Cyclosporine—rheumatoid arthritis	5.25e-05	0.000515	CcSEcCtD
Sorafenib—Pain—Triamcinolone—rheumatoid arthritis	5.24e-05	0.000513	CcSEcCtD
Sorafenib—Loss of consciousness—Prednisone—rheumatoid arthritis	5.21e-05	0.000511	CcSEcCtD
Sorafenib—Pruritus—Cyclosporine—rheumatoid arthritis	5.18e-05	0.000507	CcSEcCtD
Sorafenib—Urticaria—Hydrocortisone—rheumatoid arthritis	5.17e-05	0.000506	CcSEcCtD
Sorafenib—Angiopathy—Methotrexate—rheumatoid arthritis	5.17e-05	0.000506	CcSEcCtD
Sorafenib—Immune system disorder—Methotrexate—rheumatoid arthritis	5.15e-05	0.000504	CcSEcCtD
Sorafenib—Body temperature increased—Hydrocortisone—rheumatoid arthritis	5.14e-05	0.000504	CcSEcCtD
Sorafenib—Abdominal pain—Hydrocortisone—rheumatoid arthritis	5.14e-05	0.000504	CcSEcCtD
Sorafenib—Mediastinal disorder—Methotrexate—rheumatoid arthritis	5.13e-05	0.000503	CcSEcCtD
Sorafenib—Hypertension—Prednisone—rheumatoid arthritis	5.12e-05	0.000502	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Dexamethasone—rheumatoid arthritis	5.07e-05	0.000496	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Betamethasone—rheumatoid arthritis	5.07e-05	0.000496	CcSEcCtD
Sorafenib—Arthralgia—Prednisone—rheumatoid arthritis	5.05e-05	0.000495	CcSEcCtD
Sorafenib—Myalgia—Prednisone—rheumatoid arthritis	5.05e-05	0.000495	CcSEcCtD
Sorafenib—Alopecia—Methotrexate—rheumatoid arthritis	5.03e-05	0.000493	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—rheumatoid arthritis	5.02e-05	0.000491	CcSEcCtD
Sorafenib—Diarrhoea—Cyclosporine—rheumatoid arthritis	5.01e-05	0.000491	CcSEcCtD
Sorafenib—Gastrointestinal pain—Methylprednisolone—rheumatoid arthritis	5e-05	0.00049	CcSEcCtD
Sorafenib—Mental disorder—Methotrexate—rheumatoid arthritis	4.99e-05	0.000489	CcSEcCtD
Sorafenib—Malnutrition—Methotrexate—rheumatoid arthritis	4.96e-05	0.000486	CcSEcCtD
Sorafenib—Erythema—Methotrexate—rheumatoid arthritis	4.96e-05	0.000486	CcSEcCtD
Sorafenib—Hypersensitivity—Prednisolone—rheumatoid arthritis	4.91e-05	0.000481	CcSEcCtD
Sorafenib—Dyspepsia—Dexamethasone—rheumatoid arthritis	4.89e-05	0.000479	CcSEcCtD
Sorafenib—Dyspepsia—Betamethasone—rheumatoid arthritis	4.89e-05	0.000479	CcSEcCtD
Sorafenib—Urticaria—Triamcinolone—rheumatoid arthritis	4.87e-05	0.000477	CcSEcCtD
Sorafenib—Urticaria—Methylprednisolone—rheumatoid arthritis	4.86e-05	0.000476	CcSEcCtD
Sorafenib—Dysgeusia—Methotrexate—rheumatoid arthritis	4.86e-05	0.000476	CcSEcCtD
Sorafenib—Body temperature increased—Triamcinolone—rheumatoid arthritis	4.84e-05	0.000475	CcSEcCtD
Sorafenib—Dizziness—Cyclosporine—rheumatoid arthritis	4.84e-05	0.000474	CcSEcCtD
Sorafenib—Anaphylactic shock—Prednisone—rheumatoid arthritis	4.84e-05	0.000474	CcSEcCtD
Sorafenib—Abdominal pain—Methylprednisolone—rheumatoid arthritis	4.83e-05	0.000473	CcSEcCtD
Sorafenib—Decreased appetite—Dexamethasone—rheumatoid arthritis	4.83e-05	0.000473	CcSEcCtD
Sorafenib—Decreased appetite—Betamethasone—rheumatoid arthritis	4.83e-05	0.000473	CcSEcCtD
Sorafenib—Infection—Prednisone—rheumatoid arthritis	4.81e-05	0.000471	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Betamethasone—rheumatoid arthritis	4.8e-05	0.00047	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Dexamethasone—rheumatoid arthritis	4.8e-05	0.00047	CcSEcCtD
Sorafenib—Hypersensitivity—Hydrocortisone—rheumatoid arthritis	4.8e-05	0.00047	CcSEcCtD
Sorafenib—Fatigue—Betamethasone—rheumatoid arthritis	4.79e-05	0.00047	CcSEcCtD
Sorafenib—Fatigue—Dexamethasone—rheumatoid arthritis	4.79e-05	0.00047	CcSEcCtD
Sorafenib—Shock—Prednisone—rheumatoid arthritis	4.76e-05	0.000467	CcSEcCtD
Sorafenib—Pain—Betamethasone—rheumatoid arthritis	4.75e-05	0.000466	CcSEcCtD
Sorafenib—Pain—Dexamethasone—rheumatoid arthritis	4.75e-05	0.000466	CcSEcCtD
Sorafenib—Nervous system disorder—Prednisone—rheumatoid arthritis	4.75e-05	0.000465	CcSEcCtD
Sorafenib—Skin disorder—Prednisone—rheumatoid arthritis	4.7e-05	0.000461	CcSEcCtD
Sorafenib—Asthenia—Hydrocortisone—rheumatoid arthritis	4.67e-05	0.000457	CcSEcCtD
Sorafenib—Vomiting—Cyclosporine—rheumatoid arthritis	4.66e-05	0.000456	CcSEcCtD
Sorafenib—Rash—Cyclosporine—rheumatoid arthritis	4.62e-05	0.000452	CcSEcCtD
Sorafenib—Anorexia—Prednisone—rheumatoid arthritis	4.62e-05	0.000452	CcSEcCtD
Sorafenib—Dermatitis—Cyclosporine—rheumatoid arthritis	4.61e-05	0.000452	CcSEcCtD
Sorafenib—Pruritus—Hydrocortisone—rheumatoid arthritis	4.6e-05	0.000451	CcSEcCtD
Sorafenib—Headache—Cyclosporine—rheumatoid arthritis	4.59e-05	0.000449	CcSEcCtD
Sorafenib—Anaemia—Methotrexate—rheumatoid arthritis	4.58e-05	0.000449	CcSEcCtD
Sorafenib—Gastrointestinal pain—Betamethasone—rheumatoid arthritis	4.55e-05	0.000445	CcSEcCtD
Sorafenib—Gastrointestinal pain—Dexamethasone—rheumatoid arthritis	4.55e-05	0.000445	CcSEcCtD
Sorafenib—Hypersensitivity—Triamcinolone—rheumatoid arthritis	4.52e-05	0.000442	CcSEcCtD
Sorafenib—Hypersensitivity—Methylprednisolone—rheumatoid arthritis	4.5e-05	0.000441	CcSEcCtD
Sorafenib—Diarrhoea—Hydrocortisone—rheumatoid arthritis	4.45e-05	0.000436	CcSEcCtD
Sorafenib—Leukopenia—Methotrexate—rheumatoid arthritis	4.44e-05	0.000435	CcSEcCtD
Sorafenib—Urticaria—Dexamethasone—rheumatoid arthritis	4.42e-05	0.000433	CcSEcCtD
Sorafenib—Urticaria—Betamethasone—rheumatoid arthritis	4.42e-05	0.000433	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Prednisone—rheumatoid arthritis	4.41e-05	0.000432	CcSEcCtD
Sorafenib—Dizziness—Prednisolone—rheumatoid arthritis	4.41e-05	0.000432	CcSEcCtD
Sorafenib—Asthenia—Triamcinolone—rheumatoid arthritis	4.4e-05	0.000431	CcSEcCtD
Sorafenib—Body temperature increased—Dexamethasone—rheumatoid arthritis	4.4e-05	0.000431	CcSEcCtD
Sorafenib—Body temperature increased—Betamethasone—rheumatoid arthritis	4.4e-05	0.000431	CcSEcCtD
Sorafenib—Abdominal pain—Dexamethasone—rheumatoid arthritis	4.4e-05	0.000431	CcSEcCtD
Sorafenib—Abdominal pain—Betamethasone—rheumatoid arthritis	4.4e-05	0.000431	CcSEcCtD
Sorafenib—Asthenia—Methylprednisolone—rheumatoid arthritis	4.39e-05	0.00043	CcSEcCtD
Sorafenib—Nausea—Cyclosporine—rheumatoid arthritis	4.35e-05	0.000426	CcSEcCtD
Sorafenib—Pruritus—Triamcinolone—rheumatoid arthritis	4.34e-05	0.000425	CcSEcCtD
Sorafenib—Cough—Methotrexate—rheumatoid arthritis	4.33e-05	0.000424	CcSEcCtD
Sorafenib—Pruritus—Methylprednisolone—rheumatoid arthritis	4.33e-05	0.000424	CcSEcCtD
Sorafenib—Dizziness—Hydrocortisone—rheumatoid arthritis	4.3e-05	0.000422	CcSEcCtD
Sorafenib—Dyspepsia—Prednisone—rheumatoid arthritis	4.26e-05	0.000418	CcSEcCtD
Sorafenib—Arthralgia—Methotrexate—rheumatoid arthritis	4.22e-05	0.000414	CcSEcCtD
Sorafenib—Myalgia—Methotrexate—rheumatoid arthritis	4.22e-05	0.000414	CcSEcCtD
Sorafenib—Decreased appetite—Prednisone—rheumatoid arthritis	4.21e-05	0.000412	CcSEcCtD
Sorafenib—Rash—Prednisolone—rheumatoid arthritis	4.2e-05	0.000412	CcSEcCtD
Sorafenib—Dermatitis—Prednisolone—rheumatoid arthritis	4.2e-05	0.000411	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—rheumatoid arthritis	4.19e-05	0.000411	CcSEcCtD
Sorafenib—Diarrhoea—Methylprednisolone—rheumatoid arthritis	4.18e-05	0.00041	CcSEcCtD
Sorafenib—Fatigue—Prednisone—rheumatoid arthritis	4.17e-05	0.000409	CcSEcCtD
Sorafenib—Headache—Prednisolone—rheumatoid arthritis	4.17e-05	0.000409	CcSEcCtD
Sorafenib—Constipation—Prednisone—rheumatoid arthritis	4.14e-05	0.000406	CcSEcCtD
Sorafenib—Vomiting—Hydrocortisone—rheumatoid arthritis	4.14e-05	0.000405	CcSEcCtD
Sorafenib—Rash—Hydrocortisone—rheumatoid arthritis	4.1e-05	0.000402	CcSEcCtD
Sorafenib—Dermatitis—Hydrocortisone—rheumatoid arthritis	4.1e-05	0.000402	CcSEcCtD
Sorafenib—Headache—Hydrocortisone—rheumatoid arthritis	4.08e-05	0.000399	CcSEcCtD
Sorafenib—Dizziness—Triamcinolone—rheumatoid arthritis	4.05e-05	0.000397	CcSEcCtD
Sorafenib—Anaphylactic shock—Methotrexate—rheumatoid arthritis	4.05e-05	0.000396	CcSEcCtD
Sorafenib—Dizziness—Methylprednisolone—rheumatoid arthritis	4.04e-05	0.000396	CcSEcCtD
Sorafenib—Infection—Methotrexate—rheumatoid arthritis	4.02e-05	0.000394	CcSEcCtD
Sorafenib—Asthenia—Betamethasone—rheumatoid arthritis	3.99e-05	0.000391	CcSEcCtD
Sorafenib—Asthenia—Dexamethasone—rheumatoid arthritis	3.99e-05	0.000391	CcSEcCtD
Sorafenib—Nervous system disorder—Methotrexate—rheumatoid arthritis	3.97e-05	0.000389	CcSEcCtD
Sorafenib—Thrombocytopenia—Methotrexate—rheumatoid arthritis	3.96e-05	0.000388	CcSEcCtD
Sorafenib—Gastrointestinal pain—Prednisone—rheumatoid arthritis	3.96e-05	0.000388	CcSEcCtD
Sorafenib—Nausea—Prednisolone—rheumatoid arthritis	3.96e-05	0.000388	CcSEcCtD
Sorafenib—Pruritus—Betamethasone—rheumatoid arthritis	3.93e-05	0.000385	CcSEcCtD
Sorafenib—Pruritus—Dexamethasone—rheumatoid arthritis	3.93e-05	0.000385	CcSEcCtD
Sorafenib—Skin disorder—Methotrexate—rheumatoid arthritis	3.93e-05	0.000385	CcSEcCtD
Sorafenib—Vomiting—Triamcinolone—rheumatoid arthritis	3.9e-05	0.000382	CcSEcCtD
Sorafenib—Vomiting—Methylprednisolone—rheumatoid arthritis	3.89e-05	0.000381	CcSEcCtD
Sorafenib—Nausea—Hydrocortisone—rheumatoid arthritis	3.87e-05	0.000379	CcSEcCtD
Sorafenib—Rash—Triamcinolone—rheumatoid arthritis	3.86e-05	0.000378	CcSEcCtD
Sorafenib—Dermatitis—Triamcinolone—rheumatoid arthritis	3.86e-05	0.000378	CcSEcCtD
Sorafenib—Anorexia—Methotrexate—rheumatoid arthritis	3.86e-05	0.000378	CcSEcCtD
Sorafenib—Rash—Methylprednisolone—rheumatoid arthritis	3.86e-05	0.000378	CcSEcCtD
Sorafenib—Dermatitis—Methylprednisolone—rheumatoid arthritis	3.85e-05	0.000377	CcSEcCtD
Sorafenib—Urticaria—Prednisone—rheumatoid arthritis	3.85e-05	0.000377	CcSEcCtD
Sorafenib—Headache—Triamcinolone—rheumatoid arthritis	3.84e-05	0.000376	CcSEcCtD
Sorafenib—Headache—Methylprednisolone—rheumatoid arthritis	3.83e-05	0.000375	CcSEcCtD
Sorafenib—Abdominal pain—Prednisone—rheumatoid arthritis	3.83e-05	0.000375	CcSEcCtD
Sorafenib—Body temperature increased—Prednisone—rheumatoid arthritis	3.83e-05	0.000375	CcSEcCtD
Sorafenib—Diarrhoea—Betamethasone—rheumatoid arthritis	3.8e-05	0.000373	CcSEcCtD
Sorafenib—Diarrhoea—Dexamethasone—rheumatoid arthritis	3.8e-05	0.000373	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Methotrexate—rheumatoid arthritis	3.69e-05	0.000361	CcSEcCtD
Sorafenib—Dizziness—Dexamethasone—rheumatoid arthritis	3.68e-05	0.00036	CcSEcCtD
Sorafenib—Dizziness—Betamethasone—rheumatoid arthritis	3.68e-05	0.00036	CcSEcCtD
Sorafenib—Nausea—Triamcinolone—rheumatoid arthritis	3.64e-05	0.000357	CcSEcCtD
Sorafenib—Nausea—Methylprednisolone—rheumatoid arthritis	3.63e-05	0.000356	CcSEcCtD
Sorafenib—Dyspnoea—Methotrexate—rheumatoid arthritis	3.61e-05	0.000353	CcSEcCtD
Sorafenib—Hypersensitivity—Prednisone—rheumatoid arthritis	3.57e-05	0.000349	CcSEcCtD
Sorafenib—Dyspepsia—Methotrexate—rheumatoid arthritis	3.56e-05	0.000349	CcSEcCtD
Sorafenib—Vomiting—Dexamethasone—rheumatoid arthritis	3.54e-05	0.000346	CcSEcCtD
Sorafenib—Vomiting—Betamethasone—rheumatoid arthritis	3.54e-05	0.000346	CcSEcCtD
Sorafenib—Decreased appetite—Methotrexate—rheumatoid arthritis	3.52e-05	0.000345	CcSEcCtD
Sorafenib—Rash—Betamethasone—rheumatoid arthritis	3.51e-05	0.000343	CcSEcCtD
Sorafenib—Rash—Dexamethasone—rheumatoid arthritis	3.51e-05	0.000343	CcSEcCtD
Sorafenib—Dermatitis—Betamethasone—rheumatoid arthritis	3.5e-05	0.000343	CcSEcCtD
Sorafenib—Dermatitis—Dexamethasone—rheumatoid arthritis	3.5e-05	0.000343	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Methotrexate—rheumatoid arthritis	3.49e-05	0.000342	CcSEcCtD
Sorafenib—Fatigue—Methotrexate—rheumatoid arthritis	3.49e-05	0.000342	CcSEcCtD
Sorafenib—Headache—Dexamethasone—rheumatoid arthritis	3.48e-05	0.000341	CcSEcCtD
Sorafenib—Headache—Betamethasone—rheumatoid arthritis	3.48e-05	0.000341	CcSEcCtD
Sorafenib—Asthenia—Prednisone—rheumatoid arthritis	3.47e-05	0.00034	CcSEcCtD
Sorafenib—Pain—Methotrexate—rheumatoid arthritis	3.46e-05	0.000339	CcSEcCtD
Sorafenib—Pruritus—Prednisone—rheumatoid arthritis	3.43e-05	0.000336	CcSEcCtD
Sorafenib—Diarrhoea—Prednisone—rheumatoid arthritis	3.31e-05	0.000325	CcSEcCtD
Sorafenib—Gastrointestinal pain—Methotrexate—rheumatoid arthritis	3.31e-05	0.000324	CcSEcCtD
Sorafenib—Nausea—Dexamethasone—rheumatoid arthritis	3.3e-05	0.000324	CcSEcCtD
Sorafenib—Nausea—Betamethasone—rheumatoid arthritis	3.3e-05	0.000324	CcSEcCtD
Sorafenib—Urticaria—Methotrexate—rheumatoid arthritis	3.21e-05	0.000315	CcSEcCtD
Sorafenib—Dizziness—Prednisone—rheumatoid arthritis	3.2e-05	0.000314	CcSEcCtD
Sorafenib—Body temperature increased—Methotrexate—rheumatoid arthritis	3.2e-05	0.000313	CcSEcCtD
Sorafenib—Abdominal pain—Methotrexate—rheumatoid arthritis	3.2e-05	0.000313	CcSEcCtD
Sorafenib—Vomiting—Prednisone—rheumatoid arthritis	3.08e-05	0.000302	CcSEcCtD
Sorafenib—Rash—Prednisone—rheumatoid arthritis	3.05e-05	0.000299	CcSEcCtD
Sorafenib—Dermatitis—Prednisone—rheumatoid arthritis	3.05e-05	0.000299	CcSEcCtD
Sorafenib—Headache—Prednisone—rheumatoid arthritis	3.03e-05	0.000297	CcSEcCtD
Sorafenib—Hypersensitivity—Methotrexate—rheumatoid arthritis	2.98e-05	0.000292	CcSEcCtD
Sorafenib—Asthenia—Methotrexate—rheumatoid arthritis	2.9e-05	0.000284	CcSEcCtD
Sorafenib—Nausea—Prednisone—rheumatoid arthritis	2.88e-05	0.000282	CcSEcCtD
Sorafenib—Pruritus—Methotrexate—rheumatoid arthritis	2.86e-05	0.00028	CcSEcCtD
Sorafenib—Diarrhoea—Methotrexate—rheumatoid arthritis	2.77e-05	0.000271	CcSEcCtD
Sorafenib—Dizziness—Methotrexate—rheumatoid arthritis	2.68e-05	0.000262	CcSEcCtD
Sorafenib—Vomiting—Methotrexate—rheumatoid arthritis	2.57e-05	0.000252	CcSEcCtD
Sorafenib—Rash—Methotrexate—rheumatoid arthritis	2.55e-05	0.00025	CcSEcCtD
Sorafenib—Dermatitis—Methotrexate—rheumatoid arthritis	2.55e-05	0.00025	CcSEcCtD
Sorafenib—Headache—Methotrexate—rheumatoid arthritis	2.54e-05	0.000248	CcSEcCtD
Sorafenib—Nausea—Methotrexate—rheumatoid arthritis	2.4e-05	0.000235	CcSEcCtD
Sorafenib—CYP1A2—Metabolism—ALOX5—rheumatoid arthritis	1.44e-06	1.11e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IL1B—rheumatoid arthritis	1.43e-06	1.11e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—CD4—rheumatoid arthritis	1.43e-06	1.11e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—NOS3—rheumatoid arthritis	1.43e-06	1.11e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—NOS3—rheumatoid arthritis	1.43e-06	1.11e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—CAT—rheumatoid arthritis	1.43e-06	1.11e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IL2—rheumatoid arthritis	1.43e-06	1.1e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—PTGS2—rheumatoid arthritis	1.42e-06	1.1e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—SPP1—rheumatoid arthritis	1.42e-06	1.1e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—CXCL8—rheumatoid arthritis	1.41e-06	1.09e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—CXCL8—rheumatoid arthritis	1.41e-06	1.09e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CD80—rheumatoid arthritis	1.41e-06	1.09e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—POMC—rheumatoid arthritis	1.4e-06	1.08e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—ALB—rheumatoid arthritis	1.4e-06	1.08e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—ALB—rheumatoid arthritis	1.4e-06	1.08e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—CAT—rheumatoid arthritis	1.4e-06	1.08e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—CXCL8—rheumatoid arthritis	1.4e-06	1.08e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TYK2—rheumatoid arthritis	1.39e-06	1.07e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—IL6—rheumatoid arthritis	1.38e-06	1.07e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TYK2—rheumatoid arthritis	1.38e-06	1.07e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—ENO1—rheumatoid arthritis	1.38e-06	1.07e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CCR5—rheumatoid arthritis	1.38e-06	1.07e-05	CbGpPWpGaD
Sorafenib—ABCB1—Transmembrane transport of small molecules—ALB—rheumatoid arthritis	1.37e-06	1.06e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CCL2—rheumatoid arthritis	1.37e-06	1.06e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—FN1—rheumatoid arthritis	1.37e-06	1.06e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—ENO1—rheumatoid arthritis	1.37e-06	1.06e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—IL6R—rheumatoid arthritis	1.37e-06	1.06e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—VEGFA—rheumatoid arthritis	1.37e-06	1.06e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IL6ST—rheumatoid arthritis	1.37e-06	1.06e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—NOS3—rheumatoid arthritis	1.36e-06	1.05e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IL2RA—rheumatoid arthritis	1.36e-06	1.05e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—NOS3—rheumatoid arthritis	1.36e-06	1.05e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—TGFB1—rheumatoid arthritis	1.35e-06	1.05e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—IL2—rheumatoid arthritis	1.35e-06	1.04e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—C3—rheumatoid arthritis	1.35e-06	1.04e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—IL2—rheumatoid arthritis	1.35e-06	1.04e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—ALB—rheumatoid arthritis	1.35e-06	1.04e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—NOS3—rheumatoid arthritis	1.34e-06	1.04e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—NOS3—rheumatoid arthritis	1.34e-06	1.04e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—NFKB1—rheumatoid arthritis	1.34e-06	1.03e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ACP5—rheumatoid arthritis	1.34e-06	1.03e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—B3GNT2—rheumatoid arthritis	1.34e-06	1.03e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—POMC—rheumatoid arthritis	1.34e-06	1.03e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—IL2—rheumatoid arthritis	1.33e-06	1.03e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—VEGFA—rheumatoid arthritis	1.33e-06	1.03e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—MAPK8—rheumatoid arthritis	1.31e-06	1.02e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CD80—rheumatoid arthritis	1.31e-06	1.02e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CCL2—rheumatoid arthritis	1.31e-06	1.01e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—IL6R—rheumatoid arthritis	1.3e-06	1.01e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—POMC—rheumatoid arthritis	1.3e-06	1.01e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—rheumatoid arthritis	1.29e-06	9.99e-06	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—POMC—rheumatoid arthritis	1.29e-06	9.98e-06	CbGpPWpGaD
Sorafenib—FGFR1—Disease—TGFB1—rheumatoid arthritis	1.28e-06	9.93e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—TGFB1—rheumatoid arthritis	1.28e-06	9.9e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—MMP9—rheumatoid arthritis	1.28e-06	9.86e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—CXCL8—rheumatoid arthritis	1.27e-06	9.83e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—CXCL8—rheumatoid arthritis	1.27e-06	9.83e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—MMP9—rheumatoid arthritis	1.26e-06	9.77e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—POMC—rheumatoid arthritis	1.26e-06	9.76e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—NFKB1—rheumatoid arthritis	1.26e-06	9.75e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—LEP—rheumatoid arthritis	1.26e-06	9.7e-06	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—TGFB1—rheumatoid arthritis	1.25e-06	9.7e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—NFKB1—rheumatoid arthritis	1.25e-06	9.66e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—POMC—rheumatoid arthritis	1.25e-06	9.66e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TYK2—rheumatoid arthritis	1.25e-06	9.63e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—MAPK8—rheumatoid arthritis	1.24e-06	9.59e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—MAPK8—rheumatoid arthritis	1.23e-06	9.5e-06	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—IL6—rheumatoid arthritis	1.23e-06	9.47e-06	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—PTGS2—rheumatoid arthritis	1.22e-06	9.47e-06	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—PTGS2—rheumatoid arthritis	1.22e-06	9.47e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—NOS3—rheumatoid arthritis	1.22e-06	9.45e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CCL2—rheumatoid arthritis	1.22e-06	9.45e-06	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—TGFB1—rheumatoid arthritis	1.22e-06	9.45e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IL6R—rheumatoid arthritis	1.22e-06	9.42e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—IL2—rheumatoid arthritis	1.22e-06	9.39e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—IL2—rheumatoid arthritis	1.22e-06	9.39e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—CAT—rheumatoid arthritis	1.21e-06	9.36e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—CXCL8—rheumatoid arthritis	1.21e-06	9.33e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—BGN—rheumatoid arthritis	1.2e-06	9.31e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—CXCL8—rheumatoid arthritis	1.2e-06	9.3e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—MTHFR—rheumatoid arthritis	1.19e-06	9.23e-06	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—ALB—rheumatoid arthritis	1.19e-06	9.18e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TYK2—rheumatoid arthritis	1.19e-06	9.18e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—FN1—rheumatoid arthritis	1.18e-06	9.15e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IL6ST—rheumatoid arthritis	1.18e-06	9.11e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—rheumatoid arthritis	1.18e-06	9.11e-06	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—ALB—rheumatoid arthritis	1.18e-06	9.1e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ENO1—rheumatoid arthritis	1.17e-06	9.05e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—MTHFR—rheumatoid arthritis	1.17e-06	9.02e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—NOS3—rheumatoid arthritis	1.17e-06	9.01e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—TGFB1—rheumatoid arthritis	1.15e-06	8.92e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—IL2—rheumatoid arthritis	1.15e-06	8.91e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—rheumatoid arthritis	1.15e-06	8.9e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—IL2—rheumatoid arthritis	1.15e-06	8.89e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—MMP9—rheumatoid arthritis	1.15e-06	8.89e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—MMP9—rheumatoid arthritis	1.15e-06	8.89e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—VEGFA—rheumatoid arthritis	1.15e-06	8.85e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—NFKB1—rheumatoid arthritis	1.14e-06	8.79e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—NFKB1—rheumatoid arthritis	1.14e-06	8.79e-06	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—NOS3—rheumatoid arthritis	1.14e-06	8.78e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CD80—rheumatoid arthritis	1.13e-06	8.77e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—VEGFA—rheumatoid arthritis	1.13e-06	8.77e-06	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—NOS3—rheumatoid arthritis	1.13e-06	8.71e-06	CbGpPWpGaD
Sorafenib—BRAF—Disease—IL6—rheumatoid arthritis	1.12e-06	8.66e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—MAPK8—rheumatoid arthritis	1.12e-06	8.64e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—MAPK8—rheumatoid arthritis	1.12e-06	8.64e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TYK2—rheumatoid arthritis	1.11e-06	8.58e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ALOX5—rheumatoid arthritis	1.11e-06	8.57e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—IL6—rheumatoid arthritis	1.1e-06	8.54e-06	CbGpPWpGaD
Sorafenib—KIT—Immune System—IL6—rheumatoid arthritis	1.1e-06	8.54e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—MMP9—rheumatoid arthritis	1.09e-06	8.44e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—NOS3—rheumatoid arthritis	1.09e-06	8.42e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—MMP9—rheumatoid arthritis	1.09e-06	8.41e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CXCL8—rheumatoid arthritis	1.08e-06	8.38e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—CAT—rheumatoid arthritis	1.08e-06	8.36e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—NFKB1—rheumatoid arthritis	1.08e-06	8.35e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—POMC—rheumatoid arthritis	1.08e-06	8.34e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—NFKB1—rheumatoid arthritis	1.08e-06	8.32e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—MAPK8—rheumatoid arthritis	1.06e-06	8.2e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—MAPK8—rheumatoid arthritis	1.06e-06	8.18e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—CAT—rheumatoid arthritis	1.06e-06	8.16e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CCL2—rheumatoid arthritis	1.06e-06	8.16e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IL6R—rheumatoid arthritis	1.05e-06	8.13e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—TGFB1—rheumatoid arthritis	1.05e-06	8.12e-06	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—IL6—rheumatoid arthritis	1.05e-06	8.1e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—IL6—rheumatoid arthritis	1.05e-06	8.08e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—TGFB1—rheumatoid arthritis	1.04e-06	8.05e-06	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—PTGS2—rheumatoid arthritis	1.04e-06	8.03e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—IL2—rheumatoid arthritis	1.04e-06	8.01e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CXCL8—rheumatoid arthritis	1.03e-06	7.99e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—VEGFA—rheumatoid arthritis	1.03e-06	7.98e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—VEGFA—rheumatoid arthritis	1.03e-06	7.98e-06	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—TP53—rheumatoid arthritis	1.03e-06	7.98e-06	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—PTGS2—rheumatoid arthritis	1.03e-06	7.96e-06	CbGpPWpGaD
Sorafenib—RAF1—Disease—TGFB1—rheumatoid arthritis	1.03e-06	7.95e-06	CbGpPWpGaD
Sorafenib—KIT—Disease—IL6—rheumatoid arthritis	1.02e-06	7.88e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—MTHFR—rheumatoid arthritis	1.01e-06	7.82e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—rheumatoid arthritis	1.01e-06	7.79e-06	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—TP53—rheumatoid arthritis	1.01e-06	7.78e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—CAT—rheumatoid arthritis	9.95e-07	7.69e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—IL2—rheumatoid arthritis	9.88e-07	7.64e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—CAT—rheumatoid arthritis	9.86e-07	7.62e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—IL6—rheumatoid arthritis	9.83e-07	7.6e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MMP9—rheumatoid arthritis	9.81e-07	7.58e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—VEGFA—rheumatoid arthritis	9.8e-07	7.57e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—VEGFA—rheumatoid arthritis	9.77e-07	7.56e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—NFKB1—rheumatoid arthritis	9.7e-07	7.5e-06	CbGpPWpGaD
Sorafenib—FGFR1—Disease—IL6—rheumatoid arthritis	9.68e-07	7.48e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CXCL8—rheumatoid arthritis	9.66e-07	7.47e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—IL6—rheumatoid arthritis	9.65e-07	7.46e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TYK2—rheumatoid arthritis	9.58e-07	7.41e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—POMC—rheumatoid arthritis	9.55e-07	7.38e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—MAPK8—rheumatoid arthritis	9.54e-07	7.37e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TGFB1—rheumatoid arthritis	9.48e-07	7.33e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TGFB1—rheumatoid arthritis	9.48e-07	7.33e-06	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—IL6—rheumatoid arthritis	9.45e-07	7.31e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—IL6—rheumatoid arthritis	9.42e-07	7.28e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—NOS3—rheumatoid arthritis	9.4e-07	7.27e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MMP9—rheumatoid arthritis	9.35e-07	7.23e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—POMC—rheumatoid arthritis	9.34e-07	7.22e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—NFKB1—rheumatoid arthritis	9.25e-07	7.15e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IL2—rheumatoid arthritis	9.24e-07	7.14e-06	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—IL6—rheumatoid arthritis	9.21e-07	7.12e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—IL6—rheumatoid arthritis	9.19e-07	7.1e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—MAPK8—rheumatoid arthritis	9.1e-07	7.03e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ENO1—rheumatoid arthritis	9.03e-07	6.98e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—MTHFR—rheumatoid arthritis	9.03e-07	6.98e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TGFB1—rheumatoid arthritis	8.99e-07	6.95e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TGFB1—rheumatoid arthritis	8.97e-07	6.93e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—MTHFR—rheumatoid arthritis	8.81e-07	6.81e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—VEGFA—rheumatoid arthritis	8.81e-07	6.81e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MMP9—rheumatoid arthritis	8.74e-07	6.76e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—ALB—rheumatoid arthritis	8.71e-07	6.73e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—IL6—rheumatoid arthritis	8.7e-07	6.72e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—TP53—rheumatoid arthritis	8.65e-07	6.69e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—NFKB1—rheumatoid arthritis	8.65e-07	6.68e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—TP53—rheumatoid arthritis	8.57e-07	6.63e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—ALB—rheumatoid arthritis	8.51e-07	6.58e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—MAPK8—rheumatoid arthritis	8.5e-07	6.57e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CAT—rheumatoid arthritis	8.43e-07	6.51e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—VEGFA—rheumatoid arthritis	8.4e-07	6.49e-06	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IL6—rheumatoid arthritis	8.4e-07	6.49e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CXCL8—rheumatoid arthritis	8.34e-07	6.45e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—NOS3—rheumatoid arthritis	8.33e-07	6.44e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—MTHFR—rheumatoid arthritis	8.3e-07	6.42e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—MTHFR—rheumatoid arthritis	8.23e-07	6.36e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—NOS3—rheumatoid arthritis	8.14e-07	6.29e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—POMC—rheumatoid arthritis	8.09e-07	6.25e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TGFB1—rheumatoid arthritis	8.08e-07	6.25e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IL2—rheumatoid arthritis	7.97e-07	6.16e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—IL6—rheumatoid arthritis	7.93e-07	6.13e-06	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—IL6—rheumatoid arthritis	7.92e-07	6.12e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—VEGFA—rheumatoid arthritis	7.85e-07	6.07e-06	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—IL6—rheumatoid arthritis	7.85e-07	6.06e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TP53—rheumatoid arthritis	7.8e-07	6.03e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TP53—rheumatoid arthritis	7.8e-07	6.03e-06	CbGpPWpGaD
Sorafenib—RAF1—Disease—IL6—rheumatoid arthritis	7.75e-07	5.99e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TGFB1—rheumatoid arthritis	7.71e-07	5.96e-06	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PTGS2—rheumatoid arthritis	7.62e-07	5.89e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MMP9—rheumatoid arthritis	7.54e-07	5.83e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—NFKB1—rheumatoid arthritis	7.46e-07	5.77e-06	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PTGS2—rheumatoid arthritis	7.45e-07	5.76e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TP53—rheumatoid arthritis	7.4e-07	5.72e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TP53—rheumatoid arthritis	7.39e-07	5.71e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—ALB—rheumatoid arthritis	7.37e-07	5.7e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—MAPK8—rheumatoid arthritis	7.34e-07	5.67e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—POMC—rheumatoid arthritis	7.22e-07	5.58e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TGFB1—rheumatoid arthritis	7.2e-07	5.57e-06	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—IL6—rheumatoid arthritis	7.14e-07	5.52e-06	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—IL6—rheumatoid arthritis	7.14e-07	5.52e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—NOS3—rheumatoid arthritis	7.05e-07	5.45e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—POMC—rheumatoid arthritis	7.05e-07	5.45e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—MTHFR—rheumatoid arthritis	7.03e-07	5.44e-06	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—IL6—rheumatoid arthritis	6.78e-07	5.24e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—VEGFA—rheumatoid arthritis	6.78e-07	5.24e-06	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—IL6—rheumatoid arthritis	6.76e-07	5.23e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TP53—rheumatoid arthritis	6.65e-07	5.14e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—POMC—rheumatoid arthritis	6.64e-07	5.13e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—POMC—rheumatoid arthritis	6.58e-07	5.09e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—ALB—rheumatoid arthritis	6.58e-07	5.09e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CAT—rheumatoid arthritis	6.5e-07	5.03e-06	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PTGS2—rheumatoid arthritis	6.45e-07	4.99e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—ALB—rheumatoid arthritis	6.42e-07	4.96e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TP53—rheumatoid arthritis	6.35e-07	4.9e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—NOS3—rheumatoid arthritis	6.29e-07	4.87e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TGFB1—rheumatoid arthritis	6.22e-07	4.81e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—NOS3—rheumatoid arthritis	6.14e-07	4.75e-06	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—IL6—rheumatoid arthritis	6.09e-07	4.71e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—ALB—rheumatoid arthritis	6.05e-07	4.68e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—ALB—rheumatoid arthritis	6e-07	4.64e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TP53—rheumatoid arthritis	5.93e-07	4.58e-06	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—IL6—rheumatoid arthritis	5.81e-07	4.49e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—NOS3—rheumatoid arthritis	5.79e-07	4.48e-06	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PTGS2—rheumatoid arthritis	5.76e-07	4.45e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—NOS3—rheumatoid arthritis	5.74e-07	4.44e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—POMC—rheumatoid arthritis	5.62e-07	4.35e-06	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PTGS2—rheumatoid arthritis	5.62e-07	4.34e-06	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IL6—rheumatoid arthritis	5.43e-07	4.2e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—MTHFR—rheumatoid arthritis	5.43e-07	4.2e-06	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PTGS2—rheumatoid arthritis	5.3e-07	4.09e-06	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PTGS2—rheumatoid arthritis	5.25e-07	4.06e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ALB—rheumatoid arthritis	5.13e-07	3.96e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TP53—rheumatoid arthritis	5.12e-07	3.96e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—NOS3—rheumatoid arthritis	4.9e-07	3.79e-06	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IL6—rheumatoid arthritis	4.69e-07	3.62e-06	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PTGS2—rheumatoid arthritis	4.49e-07	3.47e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—POMC—rheumatoid arthritis	4.34e-07	3.36e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ALB—rheumatoid arthritis	3.96e-07	3.06e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—NOS3—rheumatoid arthritis	3.79e-07	2.93e-06	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PTGS2—rheumatoid arthritis	3.46e-07	2.68e-06	CbGpPWpGaD
